US 12,351,801 B2
Use of ganoderma fungal RNA molecules, drug, drug composition and delivery carrier
Zhihong Jiang, Macao (CN); Yuan Ma, Macao (CN); and Fei Ren, Macao (CN)
Assigned to MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY, Macao (CN)
Appl. No. 18/260,789
Filed by MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY, Macao (CN)
PCT Filed Nov. 17, 2022, PCT No. PCT/CN2022/132466
§ 371(c)(1), (2) Date Jul. 10, 2023,
PCT Pub. No. WO2023/165167, PCT Pub. Date Sep. 7, 2023.
Claims priority of application No. 202210203799.9 (CN), filed on Mar. 3, 2022.
Prior Publication US 2025/0019696 A1, Jan. 16, 2025
Int. Cl. C12N 15/113 (2010.01); A61K 36/074 (2006.01); A61P 11/06 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 36/074 (2013.01); A61P 11/06 (2018.01)] 7 Claims
 
1. A Ganoderma fungal RNA molecule, which is used in preparation of asthma prevention or treatment drugs,
wherein the Ganoderma fungal RNA molecule originates from transfer RNA molecule fragments (tRNA fragment, tRFs) of Ganoderma traditional Chinese medicine,
wherein a sequence of the tRFs of Ganoderma traditional Chinese medicine comprises a sequence selected from SEQ ID NO. 4 to NO. 6.